MOTS-c vs SS-31: Two Mitochondrial Peptides, Two Mechanisms
Catalogues tend to file MOTS-c and SS-31 side by side under “mitochondrial peptides”, and purchase requests often treat them as interchangeable tools for the same experiment. They are not. If your lab is sourcing SS-31 peptide in Canada alongside MOTS-c, it helps to know from the start that one is a signalling peptide encoded by the mitochondrial genome and the other is a small synthetic molecule that sticks to a lipid.
One label, two unrelated mechanisms
“Mitochondrial” describes where each compound is studied, not how it works:
- MOTS-c is a natural product of the cell. Its coding sequence sits inside mitochondrial DNA, and in the published work it acts as a signal that shifts the cell’s energy sensing and, under stress, reaches the nucleus.
- SS-31, also known as elamipretide, was designed in the laboratory. It carries no signalling function in the usual sense; it partitions into the inner mitochondrial membrane and associates with cardiolipin.
Because the targets differ, a readout that responds strongly to one compound may be flat for the other. A null result in that case is a feature of the mechanism, not proof that a vial is inactive.
MOTS-c: a peptide written into mitochondrial DNA
MOTS-c is a 16-residue peptide whose short open reading frame lies within the gene for the mitochondrial 12S ribosomal RNA. It belongs to a small family called mitochondrial-derived peptides. Humanin, the first to be described, and the six small humanin-like peptides (SHLP1 to SHLP6) are all encoded within the neighbouring 16S rRNA gene.
The mechanistic literature for MOTS-c has two main threads:
- Folate cycle and AMPK. Work from Lee and colleagues in 2015 reported that MOTS-c interferes with the folate cycle and the linked de novo purine synthesis pathway in cultured cells and mouse muscle. The downstream result was activation of AMP-activated protein kinase (AMPK), which responds to the altered energy state rather than binding the peptide directly.
- Nuclear translocation. A 2018 study by Kim and colleagues found that, under cellular stress, MOTS-c moves into the nucleus in an AMPK-dependent way and associates with genes carrying antioxidant response elements, alongside the transcription factor NRF2.
Two features make the class difficult. Because the coding sequences overlap functional rRNA genes, the peptide cannot easily be knocked out without also disturbing ribosome function. And measured endogenous levels vary widely between methods, with antibody-based detection showing specificity problems; mass-spectrometric quantitation is the stronger approach. As a result, most published MOTS-c data come from adding the synthetic peptide to cells, usually at concentrations above anything measured naturally.
Sourcing SS-31 peptide in Canada: what the molecule is
SS-31 is a tetrapeptide amide, D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2′,6′-dimethyltyrosine. It alternates aromatic and positively charged residues, and the D-arginine at the N-terminus makes it resistant to many proteases. Unusually, it accumulates at the inner mitochondrial membrane without needing a membrane potential to drive it there.
Its target, cardiolipin, is a double phospholipid: two phosphatidyl units joined through glycerol, carrying four fatty acyl tails beneath a compact head, and it is largely restricted to the inner membrane. That cone-like geometry supports the tight curvature of the cristae. Cardiolipin also sits at the contact points between respiratory complexes I, III and IV when they assemble into supercomplexes, and it helps hold cytochrome c at the membrane.
The research record developed in stages. Zhao and colleagues (2004) reported reduced reactive oxygen species and mitochondrial swelling at nanomolar concentrations in neuronal cells and isolated mitochondria. Birk and colleagues (2013) then showed high-affinity binding to cardiolipin and inhibition of cytochrome c peroxidase activity. The overall picture is of a compound acting upstream of oxidant production, by stabilising the membrane environment, rather than mopping up oxidants after they form.
The contrast at a glance:
| MOTS-c | SS-31 | |
|---|---|---|
| Origin | Encoded in mitochondrial 12S rRNA gene | Synthetic design |
| Size | 16 residues | 4 residues, C-terminal amide |
| Primary target | Folate cycle, AMPK, nuclear gene regulation | Cardiolipin in the inner membrane |
| Informative readouts | AMPK and substrate phosphorylation, gene expression | ROS, membrane potential, supercomplex assembly, cristae structure |
| Typical working range in the literature | Micromolar | Nanomolar |
| Main handling concern | Peptidase degradation in culture | Adsorption to plastic and glass |
Choosing assays that can tell them apart
A reactive oxygen species readout on its own will not separate the two, because each could lower it by a different route. A study comparing them needs a structural, a flux and a signalling measure together. The common tools, and the trap attached to each:
- Plate-based respirometry. Oxygen consumption with sequential inhibitors gives basal, ATP-linked, leak and maximal respiration. Results depend heavily on cells per well, so normalise and report seeding density.
- High-resolution respirometry using isolated mitochondria or cells with permeabilised membranes separates the contribution of individual complexes, which intact-cell plates cannot.
- Membrane potential dyes such as TMRM or JC-1 are affected by dye loading, so an uncoupler control such as FCCP belongs in every run.
- Superoxide probes like MitoSOX accumulate according to membrane potential. If the compound under test also shifts potential, the probe signal changes for reasons unrelated to superoxide.
- Supercomplex analysis by native gel electrophoresis followed by activity stains inside the gel, and cristae imaging by electron microscopy, give the structural view that suits SS-31.
- AMPK activation should be shown with phospho-Thr172 over total AMPK and a downstream substrate such as phospho-ACC. The substrate band is what demonstrates the kinase actually did something.
Use an ordinary antioxidant as a comparator, so general redox buffering can be separated from mechanism-specific effects. And normalise to mitochondrial content, for example by citrate synthase activity or by counting mtDNA copies, so that a shift in respiration is not just a shift in mitochondrial number.
Stock solutions for multi-plate campaigns
Labs often order these compounds several vials at a time, and across a multi-plate campaign small handling differences add up.
- MOTS-c dissolves readily in water but, as an unmodified linear peptide, is exposed to peptidases from serum and cell surfaces. Over a long incubation the effective concentration falls below the nominal one. Re-addition or serum-free windows are the usual answers; record whichever is used.
- SS-31 is protease-resistant, but its positive charge makes it cling to surfaces. At nanomolar working strength the loss to tubes and tips can be large, so low-binding plastics and a carrier protein in dilution buffers are worth using.
For either compound, keep lyophilised vials cold and dark, make aliquots so that no portion is thawed twice, and confirm stability under your own storage conditions if one stock will serve a study lasting weeks. Logging which vials and which lot fed which plates, as described in our note on peptide inventory records, makes a later discrepancy traceable.
Certificate checks before the first plate
Before releasing a multi-vial order to the bench, QC can confirm:
- Reversed-phase HPLC purity with the wavelength, gradient and column stated, so deletion sequences eluting near the main peak are not hidden.
- Identity by mass spectrometry (electrospray or MALDI), with the observed value compared to the theoretical one. For short sequences like these the expected mass is distinctive, which makes identity a strong check.
- Net peptide content. Counter-ions and residual water mean the weighed solid is not all peptide, and ignoring this can inflate apparent concentration substantially.
- Counter-ion identity. Trifluoroacetate left over from purification can itself affect some cell-based and viability assays; acetate-exchanged material removes that question.
Our guide to third-party and in-house testing covers what a certificate can and cannot establish. At Bulk Peptides, products are third-party tested for HPLC purity, certificates are published for some products, and vials are matched to their certificate by cap and crimp colour. Compounds in this area are listed under mitochondrial and cellular compounds, with mix-and-match volume pricing and shipping from within Canada.
Open questions in the literature
Endogenous MOTS-c levels are still disputed and method-dependent, and no binding partner has been characterised, so its mechanism is pieced together from what happens downstream. With SS-31, biophysical studies give good support to the cardiolipin binding, but linking stabilised supercomplexes to a tissue-level outcome takes several further steps, and much of the animal work uses acute injury models. Almost all the evidence for both compounds comes from isolated mitochondria, cultured cells and rodents.
MOTS-c, SS-31 and every other compound mentioned are supplied only for in-vitro laboratory research. They are not for use in humans or animals, and the findings described are from laboratory and animal studies only.
